Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.

Cholesterol plaque in artery

Physician demand could wind up being a determining factor in whether the reimbursement outlook for Amgen Inc.'s Repatha (evolocumab) improves following the long-awaited release of cardiovascular outcomes data for the PCSK9 inhibitor.

While the overall positive results of Amgen's FOURIER trial were announced last month, the level of benefit was unveiled March...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet